175 related articles for article (PubMed ID: 33826877)
1. Inflammatory bowel disease-related economic costs due to presenteeism and absenteeism.
Rankala R; Mattila K; Voutilainen M; Mustonen A
Scand J Gastroenterol; 2021 Jun; 56(6):687-692. PubMed ID: 33826877
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Inflammatory Bowel Disease in Canada 2018: Indirect Costs of IBD Care.
Kuenzig ME; Lee L; El-Matary W; Weizman AV; Benchimol EI; Kaplan GG; Nguyen GC; Bernstein CN; Bitton A; Lee K; Cooke-Lauder J; Murthy SK
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S34-S41. PubMed ID: 31294383
[TBL] [Abstract][Full Text] [Related]
3. Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics.
Mandel MD; Bálint A; Lovász BD; Gulácsi L; Strbák B; Golovics PA; Farkas K; Kürti Z; Szilágyi BK; Mohás A; Molnár T; Lakatos PL
Eur J Health Econ; 2014 May; 15 Suppl 1():S121-8. PubMed ID: 24832845
[TBL] [Abstract][Full Text] [Related]
4. Work-Related Productivity Loss and Associated Indirect Costs in Patients With Crohn's Disease or Ulcerative Colitis in the United States.
Ding Z; Muser E; Izanec J; Lukanova R; Kershaw J; Roughley A
Crohns Colitis 360; 2022 Jul; 4(3):otac023. PubMed ID: 36777416
[TBL] [Abstract][Full Text] [Related]
5. High Disease Burden Drives Indirect Costs in Employed Inflammatory Bowel Disease Patients: The WORK-IBD Study.
van Gennep S; Evers SW; Rietdijk ST; Gielen ME; de Boer NKH; Gecse KB; Ponsioen CIJ; Duijvestein M; D'Haens GR; de Boer AGEM; Löwenberg M
Inflamm Bowel Dis; 2021 Feb; 27(3):352-363. PubMed ID: 32378704
[TBL] [Abstract][Full Text] [Related]
6. The cost of illness analysis of inflammatory bowel disease.
Pakdin M; Zarei L; Bagheri Lankarani K; Ghahramani S
BMC Gastroenterol; 2023 Jan; 23(1):21. PubMed ID: 36658489
[TBL] [Abstract][Full Text] [Related]
7. The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn's & Colitis Foundation.
Park KT; Ehrlich OG; Allen JI; Meadows P; Szigethy EM; Henrichsen K; Kim SC; Lawton RC; Murphy SM; Regueiro M; Rubin DT; Engel-Nitz NM; Heller CA
Inflamm Bowel Dis; 2020 Jan; 26(1):1-10. PubMed ID: 31112238
[TBL] [Abstract][Full Text] [Related]
8. Costs of medications used to treat inflammatory bowel disease.
Rankala R; Mustonen A; Voutilainen M; Mattila K
Scand J Gastroenterol; 2024; 59(1):34-38. PubMed ID: 37642426
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life, work productivity and costs related to patients with inflammatory bowel disease in Austria.
Walter E; Hausberger SC; Groß E; Siebert U
J Med Econ; 2020 Oct; 23(10):1061-1071. PubMed ID: 32713223
[TBL] [Abstract][Full Text] [Related]
10. Global patterns of workplace productivity for people with depression: absenteeism and presenteeism costs across eight diverse countries.
Evans-Lacko S; Knapp M
Soc Psychiatry Psychiatr Epidemiol; 2016 Nov; 51(11):1525-1537. PubMed ID: 27667656
[TBL] [Abstract][Full Text] [Related]
11. Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents.
van Linschoten RCA; Visser E; Niehot CD; van der Woude CJ; Hazelzet JA; van Noord D; West RL
Aliment Pharmacol Ther; 2021 Aug; 54(3):234-248. PubMed ID: 34114667
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported symptoms are a more reliable predictor of the societal burden compared to established physician-reported activity indices in inflammatory bowel disease: a cross-sectional study.
Decker B; Tuzil J; Lukas M; Cerna K; Bortlik M; Velackova B; Pilnackova B; Dolezal T
Expert Rev Gastroenterol Hepatol; 2023 Jan; 17(1):99-108. PubMed ID: 36537197
[TBL] [Abstract][Full Text] [Related]
13. Indirect Costs of Inflammatory Bowel Diseases: A Comparison of Patient-Reported Outcomes Across 12 European Countries.
Holko P; Kawalec P; Sajak-Szczerba M; Avedano L; Mossakowska M
Inflamm Bowel Dis; 2023 May; 29(5):752-762. PubMed ID: 35792501
[TBL] [Abstract][Full Text] [Related]
14. The 2023 Impact of Inflammatory Bowel Disease in Canada: Indirect (Individual and Societal) and Direct Out-of-Pocket Costs.
Kuenzig ME; Im JHB; Coward S; Windsor JW; Kaplan GG; Murthy SK; Benchimol EI; Bernstein CN; Bitton A; Jones JL; Lee K; Peña-Sánchez JN; Rohatinsky N; Ghandeharian S; Jones May T; Tabatabavakili S; Jogendran R; Weinstein J; Khan R; Hazan E; Browne M; Davis T; Goddard Q; Gorospe J; Latos K; Mason K; Kerr J; Balche N; Sklar A; Targownik LE
J Can Assoc Gastroenterol; 2023 Sep; 6(Suppl 2):S16-S22. PubMed ID: 37674495
[TBL] [Abstract][Full Text] [Related]
15. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study.
van der Valk ME; Mangen MJ; Leenders M; Dijkstra G; van Bodegraven AA; Fidder HH; de Jong DJ; Pierik M; van der Woude CJ; Romberg-Camps MJ; Clemens CH; Jansen JM; Mahmmod N; van de Meeberg PC; van der Meulen-de Jong AE; Ponsioen CY; Bolwerk CJ; Vermeijden JR; Siersema PD; van Oijen MG; Oldenburg B;
Gut; 2014 Jan; 63(1):72-9. PubMed ID: 23135759
[TBL] [Abstract][Full Text] [Related]
16. IBD Disability Index Is Associated With Both Direct and Indirect Costs of Inflammatory Bowel Disease.
Shafer LA; Shaffer S; Witt J; Nugent Z; Bernstein CN
Inflamm Bowel Dis; 2022 Aug; 28(8):1189-1197. PubMed ID: 34636400
[TBL] [Abstract][Full Text] [Related]
17. Savings in social expenditures for work incapacity in patients with inflammatory bowel disease depend on access to innovative therapies in Poland.
Zagórowicz E; Binowski G; Strządała D; Pruszko C; Kucha P; Reguła J
Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):695-703. PubMed ID: 38526938
[TBL] [Abstract][Full Text] [Related]
18. Presenteeism in Inflammatory Bowel Diseases: A Hidden Problem with Significant Economic Impact.
Zand A; van Deen WK; Inserra EK; Hall L; Kane E; Centeno A; Choi JM; Ha CY; Esrailian E; DʼHaens GR; Hommes DW
Inflamm Bowel Dis; 2015 Jul; 21(7):1623-30. PubMed ID: 26070004
[TBL] [Abstract][Full Text] [Related]
19. Burden of Crohn's disease in the United States: long-term healthcare and work-loss related costs.
Manceur AM; Ding Z; Muser E; Obando C; Voelker J; Pilon D; Kinkead F; Lafeuille MH; Lefebvre P
J Med Econ; 2020 Oct; 23(10):1092-1101. PubMed ID: 32609019
[TBL] [Abstract][Full Text] [Related]
20. [ECONOMIC BURDEN AND CURRENT STATUS OF THE DRUG SUPPLY MANAGEMENT FOR IMMUNE INFLAMMATORY DISEASES (BY EXAMPLE OF ULCERATIVE COLITIS AND CROHN'S DISEASE)].
Veselov AV; Belousova EA; Bakulin IG; Uspenskiy YP; Dreval RO; Shkurko TV; Kashnikov BN; Fominykh YA; Knyazev OV; Romanov RI; Skalinskaia MI; Shipitsyn VV
Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2020 Oct; 28(Special Issue):1137-1145. PubMed ID: 33219771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
